Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab demonstrated a high objective response rate, including complete responses in patients with advanced melanoma. METHODS: In this double-blind study, 142 treatment-naïve patient...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Postow, Michael A., Chesney, Jason, Pavlick, Anna C., Robert, Caroline, Grossmann, Kenneth, McDermott, David, Linette, Gerald P., Meyer, Nicolas, Giguere, Jeffrey K., Agarwala, Sanjiv S., Shaheen, Montaser, Ernstoff, Marc S., Minor, David, Salama, April K., Taylor, Matthew, Ott, Patrick A., Rollin, Linda M., Horak, Christine, Gagnier, Paul, Wolchok, Jedd D., Hodi, F. Stephen
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5744258/
https://ncbi.nlm.nih.gov/pubmed/25891304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1414428
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items